Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Files An 8-K Other Events
Item8.01.
| Other Events. |
On December4, 2016, Karyopharm Therapeutics Inc. (the Company)
issued a press release announcing updated results from its Phase
2b STORM study of selinexor (KPT-330). A copy of the press
release is filed as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.
On December4, 2016, the Company issued a press release announcing
updated results from an investigator-sponsored Phase 2 SAIL study
of selinexor. A copy of the press release is filed as Exhibit
99.2 to this Current Report on Form 8-K and is incorporated
herein by reference.
On December5, 2016, the Company issued a press release announcing
updated results from the dose-escalation portion of its ongoing
Phase 1b/2 STOMP study of selinexor. A copy of the press release
is filed as Exhibit 99.3 to this Current Report on Form 8-K and
is incorporated herein by reference.
| Item9.01. | Financial Statements and Exhibits. |
(d) Exhibits
The Exhibits to this Current Report on Form 8-K are listed in the
Exhibit Index attached hereto.
About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Recent Trading Information
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) closed its last trading session up +0.26 at 9.13 with 274,866 shares trading hands.
